Overview
On 17 October 2019, orphan designation EU/3/19/2212 was granted by the European Commission to Minoryx Therapeutics S.L., Spain, for leriglitazone (also known as MIN-102) for the treatment of Friedreich’s ataxia.
Key facts
Active substance |
leriglitazone
|
Intended use |
Treatment of Friedreich’s ataxia
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/19/2212
|
Date of designation |
17/10/2019
|
Sponsor |
Minoryx Therapeutics S.L. |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: